
Nadine Attal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8643390/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology, The, 2015, 14, 162-173.	10.2	2,776
2	Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 2005, 114, 29-36.	4.2	1,969
3	Neuropathic pain. Nature Reviews Disease Primers, 2017, 3, 17002.	30.5	1,360
4	Prevalence of chronic pain with neuropathic characteristics in the general population. Pain, 2008, 136, 380-387.	4.2	1,355
5	Development and validation of the Neuropathic Pain Symptom Inventory. Pain, 2004, 108, 248-257.	4.2	1,031
6	The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain, 2019, 160, 53-59.	4.2	571
7	Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain, 2017, 158, 261-272.	4.2	462
8	Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain, 2013, 154, 1807-1819.	4.2	428
9	Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Annals of Neurology, 2008, 64, 274-283.	5.3	362
10	The specific disease burden of neuropathic pain: Results of a French nationwide survey. Pain, 2011, 152, 2836-2843.	4.2	327
11	Effects of unilateral repetitive transcranial magnetic stimulation of the motor cortex on chronic widespread pain in fibromyalgia. Brain, 2007, 130, 2661-2670.	7.6	239
12	Long-term maintenance of the analgesic effects of transcranial magnetic stimulation in fibromyalgia. Pain, 2011, 152, 1478-1485.	4.2	217
13	<scp>EAN</scp> guidelines on central neurostimulation therapy in chronic pain conditions. European Journal of Neurology, 2016, 23, 1489-1499.	3.3	205
14	Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Revue Neurologique, 2020, 176, 325-352.	1.5	184
15	Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2016, 15, 555-565.	10.2	176
16	Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain, 2017, 158, 1446-1455.	4.2	150
17	Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurology, The, 2018, 17, 456-466.	10.2	149
18	Psychiatric coâ€morbidities in patients with chronic peripheral neuropathic pain: A multicentre cohort study. European Journal of Pain, 2013, 17, 1547-1557.	2.8	130

NADINE ATTAL

#	Article	lF	CITATIONS
19	The Neuropathic Components of Chronic Low Back Pain: A Prospective Multicenter Study Using the DN4 Questionnaire. Journal of Pain, 2011, 12, 1080-1087.	1.4	124
20	Pharmacological treatments of neuropathic pain: The latest recommendations. Revue Neurologique, 2019, 175, 46-50.	1.5	119
21	Repetitive transcranial magnetic stimulation and transcranial direct-current stimulation in neuropathic pain due to radiculopathy. Pain, 2016, 157, 1224-1231.	4.2	74
22	Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Reports, 2021, 6, e884.	2.7	74
23	Quantitative sensory testing using DFNS protocol in Europe. Pain, 2016, 157, 750-758.	4.2	71
24	Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. Brain, 2021, 144, 3328-3339.	7.6	59
25	Effect of Alexithymia and Emotional Repression on Postsurgical Pain in Women With Breast Cancer: A Prospective Longitudinal 12-Month Study. Journal of Pain, 2016, 17, 90-100.	1.4	45
26	No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter cohort of patients with neuropathy. Pain, 2021, 162, 718-727.	4.2	44
27	Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a new algorithm. Pain, 2021, 162, 1038-1046.	4.2	41
28	Translational neuropathic pain research. Pain, 2019, 160, S23-S28.	4.2	35
29	Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. Pain, 2021, 162, 2578-2589.	4.2	28
30	Advances in the treatment of neuropathic pain. Current Opinion in Neurology, 2021, 34, 631-637.	3.6	26
31	The multiple challenges of neuropathic pain. Neuroscience Letters, 2019, 702, 6-10.	2.1	22
32	Contralateral Sensory and Pain Perception Changes in Patients With Unilateral Neuropathy. Neurology, 2021, 97, e389-e402.	1.1	22
33	French guidelines for neuropathic pain: An update and commentary. Revue Neurologique, 2021, 177, 834-837.	1.5	18
34	Spinal cord injury pain. Revue Neurologique, 2021, 177, 606-612.	1.5	16
35	eDOL mHealth App and Web Platform for Self-monitoring and Medical Follow-up of Patients With Chronic Pain: Observational Feasibility Study. JMIR Formative Research, 2022, 6, e30052.	1.4	8
36	Real-Life Management Pathways for Chronic Peripheral Neuropathic Pain at Tertiary Pain Clinics in France. Pain Medicine, 2021, 22, 875-882.	1.9	7

NADINE ATTAL

#	Article	IF	CITATIONS
37	Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies. Current Medical Research and Opinion, 2022, , 1-18.	1.9	3
38	Pain research in 2018: the year of translational studies. Lancet Neurology, The, 2019, 18, 13-15.	10.2	1
39	Discussion suite aux communicationsÂ: «ÂToxine botulinique A et douleurs neuropathiques» et «ÂToxine botulique de type A et migraine chroniqueÂ: une revue des données récentes». Bulletin De L'Academie Nationale De Medecine, 2020, 204, 395-396.	0.0	0
40	Toxine botulinique A et douleurs neuropathiques. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 379-385.	0.0	0